Find in Library

959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial

oleh: Harpreet Singh, Jason Luke, Mamta Kalra, Martin Wermke, Dejka Araujo, Ali Mohamed, Winfried Alsdorf, Apostolia-Maria Tsimberidou, Andrea Mayer-Mokler, Arun Satelli, Carsten Reinhardt, Dominik Maurer, George Jr Blumenschein, Kerstin Guenther, Manik Chatterjee, Norbert Hilf, Regina Mendrzyk, Steffen Walter, Stephen Eck, Tobias AW Holderried, Toni Weinschenk, Van Morris, Cedrik M Britten